rs16830236
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001164507.2(NEB):c.18113A>G(p.Asn6038Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00212 in 1,613,174 control chromosomes in the GnomAD database, including 71 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Synonymous variant affecting the same amino acid position (i.e. N6038N) has been classified as Likely benign.
Frequency
Consequence
NM_001164507.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NEB | NM_001164507.2 | c.18113A>G | p.Asn6038Ser | missense_variant | 114/182 | ENST00000427231.7 | |
NEB | NM_001164508.2 | c.18113A>G | p.Asn6038Ser | missense_variant | 114/182 | ENST00000397345.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NEB | ENST00000397345.8 | c.18113A>G | p.Asn6038Ser | missense_variant | 114/182 | 5 | NM_001164508.2 | P5 | |
NEB | ENST00000427231.7 | c.18113A>G | p.Asn6038Ser | missense_variant | 114/182 | 5 | NM_001164507.2 | A2 |
Frequencies
GnomAD3 genomes ? AF: 0.0108 AC: 1643AN: 152170Hom.: 31 Cov.: 32
GnomAD3 exomes AF: 0.00289 AC: 718AN: 248434Hom.: 11 AF XY: 0.00212 AC XY: 285AN XY: 134724
GnomAD4 exome AF: 0.00120 AC: 1758AN: 1460886Hom.: 39 Cov.: 31 AF XY: 0.00106 AC XY: 767AN XY: 726624
GnomAD4 genome ? AF: 0.0109 AC: 1659AN: 152288Hom.: 32 Cov.: 32 AF XY: 0.0106 AC XY: 789AN XY: 74472
ClinVar
Submissions by phenotype
Nemaline myopathy 2 Benign:3
Benign, criteria provided, single submitter | clinical testing | Invitae | Jan 31, 2024 | - - |
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
not specified Benign:2
Likely benign, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | - | Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | May 12, 2016 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | May 25, 2018 | - - |
Nemaline myopathy 2;C5543431:Arthrogryposis multiplex congenita 6 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 20, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at